Click to check your cart0

Influenza in Urgent Care: 2024-2025 Season Update (Pharmacology CME and Infectious Disease CME)

Below is a free preview. Log in or subscribe for full access. Or, get a free sample article Evidence-Based Management of Angioedema in Urgent Care:
Please provide a valid email address.

Action

Patient presents with influenza-like illness (fever >37.8°C [100°F] and cough or sore throat)


Decision

What is the current local disease prevalence?


Background

In periods of low influenza activity (ie, summertime), a rapid test will have its lowest PPV and its highest negative predictive value (NPV) and is more likely to yield false-positive results—up to 50%, in 1 study—when the disease prevalence drops below 5%.61^{61}  Conversely, in times of peak influenza activity (during an epidemic or pandemic), a rapid test will have a higher PPV and lower NPV and is more likely to produce a false-negative result. Because all modalities of influenza testing are highly specific, most positive test results can be trusted to be true positives regardless of pretest probability of influenza.62,63^{62,63}

Find your community Influenze-Like-Illness activity at the CDC Weekly Influenza Surveillance Report

Evidence-based medicine requires a critical appraisal of the literature based upon study methodology and number of subjects. Not all references are equally robust. The findings of a large, prospective, randomized, and blinded trial should carry more weight than a case report.

To help the reader judge the strength of each reference, pertinent information about the study, such as the type of study and the number of patients in the study is included in bold type following the references, where available. The most informative references cited in this paper, as determined by the authors, are noted by an asterisk (*) next to the number of the reference.

  1. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis. 2006;12(1):15-22. (Historical article) 
  2. Centers for Disease Control and Prevention. 1968 Pandemic (H3N2 virus). Updated January 2, 2019. Accessed November 6, 2024. Available at: https://archive.cdc.gov/www_cdc_gov/flu/ pandemic-resources/1968-pandemic.html (CDC website) 
  3. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179-186. (Retrospective study) 
  4. Centers for Disease Control and Prevention. Flu Resources for Business. Reviewed March 22, 2024. Accessed November 6, 2024. Available at: https://archive.cdc.gov/www_cdc_gov/flu/business/index.htm (CDC website) 
  5. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086-5096. (Epidemiologic surveillance study) 
  6. * Mossad SB. Another influenza season in the shadow of the COVID-19 pandemic. Cleve Clin J Med. 2021;88(11):594-597. (Commentary) DOI: 10.3949/ccjm.88a.21095 
  7. Centers for Disease Control and Prevention. Public Health Response to Severe Influenza. Reviewed February 28, 2018. Accessed November 6, 2024. Available at: https://archive.cdc.gov/www_cdc_gov/grand-rounds/pp/2018/20180116-severe-influenza.html (CDC website) 
  8. Centers for Disease Control and Prevention. CDC Novel H1N1 Flu: 2009 H1N1 Early Outbreak and Disease Characteristics. Updated October 27, 2009. Accessed November 6, 2024. Available at: https://archive.cdc.gov/www_cdc_gov/h1n1flu/surveillanceqa.htm (CDC website) 
  9. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460(7258):1021-1025. (Basic science research) 
  10. Monto AS. Epidemiology of influenza. Vaccine. 2008;26 Suppl 4:D45-48. (Epidemiologic history) 
  11. Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med. 2000;51:407-421. (Epidemiologic history) 
  12. Centers for Disease Control and Prevention. FluView: a weekly influenza surveillance report prepared by the Influenza Division. Accessed November 6, 2024. Available at: https://www.cdc.gov/fluview/index.html (CDC website) 
  13. Butel J. Orthomyxoviruses (influenza viruses). In: Brooks GF, Butel JS, Morse SA, eds. Jawetz, Melnick & Adelberg’s Medical Microbiology: McGraw Hill Medical; 2007. (Textbook chapter) 
  14. Palese P. Influenza: old and new threats. Nat Med. 2004;10(12 Suppl):S82-87. (Basic science history) 
  15. Centers for Disease Control and Prevention. Avian Influenza Type A Viruses. Accessed November 11, 2024. Available at: https://www.cdc.gov/bird-flu/about/ (CDC website) 
  16. Charostad J, Rezaei Zadeh Rukerd M, Mahmoudvand S, et al. A comprehensive review of highly pathogenic avian influenza (HPAI) H5N1: An imminent threat at doorstep. Travel Med Infect Dis. 2023;55:102638. (Review article) 
  17. Centers for Disease Control and Prevention. CDC A(H5N1) Bird Flu Response Update October 11, 2024. Accessed November 11, 2024. Available at: https://www.cdc.gov/bird-flu/spotlights/ h5n1-response-10112024.html (CDC website) 
  18. Centers for Disease Control and Prevention. H5 Bird Flu: Current Situation. Accessed November 6, 2024. Available at: https://www.cdc.gov/bird-flu/situation-summary/index.html (CDC website) 
  19. California Department of Public Health. Avian Influenza A(H5N1): Information for Health Professionals. Accessed November 11, 2024. Available at: https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/BirdFluHP.aspx (Website) 
  20. Centers for Disease Control and Prevention. Interim Guidance on the Use of Antiviral Medications for Treatment of Human Infections with Novel Influenza A Viruses Associated with Severe Human Disease. Accessed November 11, 2024. Available at: https://www.cdc.gov/bird-flu/hcp/novel-av-treatment-guidance/ (CDC website) 
  21. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006;12(1):9-14. (Review article) 
  22. Centers for Disease Control and Prevention. CDC Seasonal Flu Vaccine Effectiveness Studies. Updated August 14, 2024. Accessed November 6, 2024. Available at: https://www.cdc.gov/flu-vaccines-work/php/effectiveness-studies/index.html (CDC website) 
  23. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med. 2003;348(9):867-868. (Case report) 
  24. Sato M, Hosoya M, Kato K, et al. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J. 2005;24(10):931-932. (Prospective study; 63 patients) 
  25. Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2007;56(14):325-329. (Case reports) 
  26. Barry JM. The Great Influenza: The Epic Story of the Deadliest Plague in History. Viking; 2004. (Book) 
  27. * World Health Organization. Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season. Updated February 23, 2024. Available at: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season (WHO recommendations) 
  28. * Grohskopf LA. Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices – United States, 2024-25 influenza season. MMWR Morb Mortal Wkly Rep. 2024;73(No. RR-5):1-25. Available at: https://www.cdc.gov/flu/media/pdfs/2024/08/acip-2024-25-summary-of-recommendations.pdf (Recommendation) 
  29. Centers for Disease Control and Prevention. Influenza activity in the United States during the 2023-2024 season and composition of the 2024-2025 influenza vaccine. Updated September 27, 2024. Available at: https://www.cdc.gov/flu/whats-new/flu-summary-2023-2024.html (CDC website) 
  30. Rolfes M, Foppa I, Garg S, et al. Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths in the United States — 2019–2020 Influenza Season. Available at: https://www.cdc.gov/flu/about/burden/2019-2020/archive-09292021.html (CDC website) 
  31. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942-951. (Systematic review and meta-analysis; 56 papers included in meta-analysis) 
  32. Centers for Disease Control and Prevention. People at Increased Risk for Flu Complications. Updated September 11, 2024. Available at: https://www.cdc.gov/flu/highrisk/index.htm (CDC website) 
  33. Centers for Disease Control and Prevention. Flu Vaccines and People with Egg Allergies. Updated September 17, 2024. Accessed November 11, 2024. Available at: https://www.cdc.gov/flu/vaccines/egg-allergies.html (CDC website) 
  34. * Greenhawt M, Turner PJ, Kelso JM. Administration of influenza vaccines to egg allergic recipients: a practice parameter update 2017. Ann Allergy Asthma Immunol. 2018;120(1):49-52. (Practice guideline) DOI: 10.1016/j.anai.2017.10.020
  35. * Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200(2):172- 180. (Randomized controlled trial; 3837 patients) DOI: 10.1086/599790 
  36. Donahue JG, Kieke BA, King JP, et al. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12. Vaccine. 2017;35(40):5314-5322. (Case-control study, 485 cases) 
  37. Donahue JG, Kieke BA, King JP, et al. Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15. Vaccine. 2019;37(44):6673- 6681. (Case-control study; 1236 cases) 
  38. * Immunization Action Coalition. Ask the Experts: Influenza. Updated September 5, 2024. Accessed November 11, 2024. Available at: https://www.immunize.org/ask-experts/topic/influenza/ (Website) 
  39. * Kroger A, Bahta L, Long S, Sanchez P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Updated July 22, 2024. Accessed on November 11, 2024. Available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html (Practice recommendations) 
  40. * Toback S, Galiza E, Cosgrove C, et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10(2):167-179. (Randomized controlled trial; 400 patients) DOI: 10.1016/S2213-2600(21)00409-4 
  41. Centers for Disease Control and Prevention. Getting a flu vaccine and other recommended vaccines at the same time. Updated September 17, 2024. Accessed on November 11, 2024. Available at: https://www.cdc.gov/flu/vaccines/coadministration.html (CDC website) 
  42. Centers for Disease Control and Prevention. About Influenza. Updated August 13, 2024. Accessed November 11, 2024. Available at: https://www.cdc.gov/flu/about/index.html (CDC website) 
  43. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003-1032. (Clinical practice guideline) 
  44. VanWormer JJ, Sundaram ME, Meece JK, et al. A cross-sectional analysis of symptom severity in adults with influenza and other acute respiratory illness in the outpatient setting. BMC Infect Dis. 2014;14:231. (Prospective study; 2374 patients) 
  45. Boivin G, Hardy I, Tellier G, et al. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis. 2000;31(5):1166-1169. (Basic science research) 
  46. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000;160(21):3243-3247. (Retrospective study; 3744 patients) 
  47. Dixon BE, Wools-Kaloustian K, Fadel WF, et al. Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: results from a statewide epidemio-logical study. PLoS One. 2021;16(3):e0241875. (Cross-sectional population study; 8214 patients) 
  48. Silvennoinen H, Peltola V, Lehtinen P, et al. Clinical presentation of influenza in unselected children treated as outpatients. Pediatr Infect Dis J. 2009;28(5):372-375. (Prospective study; 2231 patients) 
  49. * Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis. 2003;36(3):299-305. (Retrospective study; 15,420 patients) DOI: 10.1086/345909 
  50. * Lim WS. Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health. Thorax. 2007;62(Suppl 1):1-46. (Clinical practice guidelines – UK) DOI: 10.1136/thx.2006.073080 
  51. * Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68(6):e1-e47. (Clinical practice guideline) DOI: 10.1093/cid/ciy874 
  52. Young S, Illescas P, Nicasio J, et al. Diagnostic accuracy of the real- time PCR cobas® Liat® Influenza A/B assay and the Alere i Influenza A&B NEAR isothermal nucleic acid amplification assay for the detection of influenza using adult nasopharyngeal specimens. J Clin Virol. 2017;94:86-90. (Basic science research) 
  53. Hazelton B, Gray T, Ho J, et al. Detection of influenza A and B with the Alere™ i Influenza A & B: a novel isothermal nucleic acid amplification assay. Influenza Other Respir Viruses. 2015;9(3):151-154. (Basic science research) 
  54. Bonner AB, Monroe KW, Talley LI, et al. Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial. Pediatrics. 2003;112(2):363-367. (Randomized prospective controlled trial; 418 patients) 
  55. Noyola DE, Demmler GJ. Effect of rapid diagnosis on management of influenza A infections. Pediatr Infect Dis J. 2000;19(4):303-307. (Retrospective study; 1530 patients) 
  56. Esposito S, Marchisio P, Morelli P, et al. Effect of a rapid influenza diagnosis. Arch Dis Child. 2003;88(6):525-526. (Randomized controlled trial; 957 patients) 
  57. D’Heilly SJ, Janoff EN, Nichol P, et al. Rapid diagnosis of influenza infection in older adults: influence on clinical care in a routine clinical setting. J Clin Virol. 2008;42(2):124-128. (Retrospective study; 311 patients)
  58. Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med. 2007;167(4):354-360. (Retrospective study; 311 patients) 
  59. Benito-Fernández J, Vázquez-Ronco MA, Morteruel-Aizkuren E, et al. Impact of rapid viral testing for influenza A and B viruses on management of febrile infants without signs of focal infection. Pediatr Infect Dis J. 2006;25(12):1153-1157. (Prospective study; 206 patients) 
  60. Sharma V, Dowd MD, Slaughter AJ, et al. Effect of rapid diagnosis of influenza virus type A on the emergency department management of febrile infants and toddlers. Arch Pediatr Adolesc Med. 2002;156(1):41-43. (Retrospective study; 47 patients)
  61. Grijalva CG, Poehling KA, Edwards KM, et al. Accuracy and interpretation of rapid influenza tests in children. Pediatrics. 2007;119(1):e6-11. (Prospective study; 2797 patients) 
  62. Centers for Disease Control and Prevention. Information for Clinicians on Rapid Diagnostic Testing for Influenza. Updated September 17, 2024. Accessed November 11, 2024. Available at: https://www.cdc.gov/flu/hcp/testing-methods/rapidclin.html (CDC website) 
  63. * Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J. 2003;22(2):164-177. (Systematic review) 
  64. Stein J, Louie J, Flanders S, et al. Performance characteristics of clinical diagnosis, a clinical decision rule, and a rapid influenza test in the detection of influenza infection in a community sample of adults. Ann Emerg Med. 2005;46(5):412-419. (Prospective study, 258 patients) 
  65. * Ozaras R, Cirpin R, Duran A, et al. Influenza and COVID-19 coinfection: report of six cases and review of the literature. J Med Virol. 2020;92(11):2657-2665. (Case reports and literature review; 6 patients) DOI: 10.1002/jmv.26125 
  66. Centers for Disease Control and Prevention. Clinical Guidance for Patients With Acute Respiratory Illness not Being Hospitalized When SARS-CoV-2 and Influenza Viruses are Co- Circulating. Updated December 6, 2023. Accessed November 11, 2024. Available at: https://www.cdc.gov/flu/hcp/clinical-guidance/testing-guidance-for-outpatient.html (CDC website) 
  67. Centers for Disease Control and Prevention. Testing and Respiratory Viruses. Updated March 1, 2024. Accessed November 11, 2024. Available at: https://www.cdc.gov/respiratory-viruses/prevention/testing.html (CDC website) 
  68. Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians. Updated December 8, 2023. Accessed November 12, 2024. Available at: https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html CDC website) 
  69. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics. 2009;124(1):170-178. (Retrospective study; 5355 patients) 
  70. Nakamura S, Miyazaki T, Izumikawa K, et al. Efficacy and safety of intravenous peramivir compared with oseltamivir in high- risk patients infected with influenza A and B viruses: a multi- center randomized controlled study. Open Forum Infect Dis. 2017;4(3):ofx129. (Randomized control study; 92 patients) 
  71. Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians. Updated September 9, 2022. Accessed November 10, 2022. Available at: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (CDC website) 
  72. Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015;385(9979):1729-1737. (Meta-analysis; 4328 patients) 
  73. Murphy KR, Eivindson A, Pauksens K, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clinical Drug Investigation. 2000;20(5):337-349. (Randomized controlled trial; 525 patients) 
  74. GlaxoSmithKline. Highlights of Prescribing Information. Revised 10/2023. Accessed November 12, 2024. Available at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Relenza/pdf/RELENZA-PI-PIL-IFU.PDF (Prescribing information) 
  75. Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54(11):4568- 4574. (Prospective study; 300 patients) 
  76. U.S. Food and Drug Administration. Rapivab Prescribing Information. Revised 06/2024. Accessed November 12, 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/206426s009lbl.pdf (Drug prescribing information) 
  77. Lee J, Park JH, Jwa H, et al. Comparison of efficacy of intravenous peramivir and oral oseltamivir for the treatment of influenza: systematic review and meta-analysis. Yonsei Med J. 2017;58(4):778- 785. (Systematic review; 1676 patients) 
  78. Pinto LH, Lamb RA. Influenza virus proton channels. Photochem Photobiol Sci. 2006;5(6):629-632. (Basic science research) 
  79. U.S. Food and Drug Administration. Xofluza prescribing information. 2018. Accessed November 12, 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf (FDA prescribing information) 
  80. Ilyushina NA, Govorkova EA, Webster RG. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology. 2005;341(1):102- 106. (Basic science research) 
  81. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006;295(8):891- 894. (Prospective study; 209 patients) 
  82. De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006;5(12):1015-1025. (Basic science review) 
  83. * Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006;367(9507):303-313. (Systematic review; 51 randomized controlled trials) DOI: 10.1016/S0140-6736(06)67970-1 
  84. * Jefferson T, Demicheli V, Di Pietrantonj C, et al. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev. 2006;2006(2):CD001169. (Cochrane review; 20 prophylaxis trials, 13 treatment trials) DOI: 10.1002/14651858.CD001169.pub3 
  85. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis. 2009;15(4):552-560. (Prospective surveillance study) 
  86. Centers for Disease Control and Prevention. Influenza Antiviral Drug Baloxavir Marboxil. Updated September 7, 2022. Accessed November 12, 2024. Available at: https://www.cdc.gov/flu/treatment/baloxavir-marboxil.html (CDC website) 
  87. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admit-ted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395-404. (Meta-analysis of data from 2009-2010 pandemic; 78 studies, 29,234 patients) 
  88. American Academy of Pediatrics Committee on Infectious Diseases. Policy statement. Recommendations for prevention and control of influenza in children, 2021-2022. Pediatrics. 2022;150(4):e2022059274. (Policy statement) 
  89. Butler CC, van der Velden AW, Bongard E, et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet. 2020;395(10217):42-52. (Randomized controlled trial; 3266 patients) 
  90. Neuzil KM, Wright PF, Mitchel EF, Jr., et al. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr. 2000;137(6):856-864. (Retrospective study) 
  91. World Health Organization. Influenza seasonal. Accessed November 12, 2024. Available at: https://www.who.int/health-topics/influenza-seasonal (WHO website) 
  92. American College of Emergency Physicians. National Strategic Plan for Emergency Department Management of Outbreaks of Novel H1N1 Influenza. Accessed November 12, 2024. Available at: https://www.acep.org/siteassets/uploads/uploaded-files/acep/clinical-and-practice-management/resources/publichealth/h1n1/h1n1-strategicplan.pdf (ACEP strategic plan) 


Publication Information
Authors

Tracey Quail Davidoff, MD, FCUCM; Christopher Chao,MD

Peer Reviewed By

Lisa M. Campanella-Coppo, MD, FACEP

Publication Date

December 1, 2024

CME Expiration Date

December 1, 2027    CME Information

CME Credits

4 AMA PRA Category 1 Credits™. 4 AOA Category 2-B Credits.
4 AAFP Prescribed Credits
Specialty CME Credits: Included as part of the 4 credits, this CME activity is eligible for 2 Pharmacology CME credits and 4 Infectious Disease CME credits.

Get Permission

Content you might be interested in
Get A Sample Issue Of Emergency Medicine Practice
Enter your email to get your copy today! Plus receive updates on EB Medicine every month.
Please provide a valid email address.